News >

Breadth of RCC Treatment Options Includes Novel Agents and Combo Strategies

Jessica Hergert
Published: Monday, Dec 02, 2019

Kathryn E. Beckermann, MD, PhD, an instructor of medicine in the Division of Hematology/Oncology in the Department of Medicine at Vanderbilt University Medical Center

Kathryn E. Beckermann, MD, PhD

A slew of monotherapy and combination approvals has reshaped the frontline treatment landscape for patients with metastatic renal cell carcinoma (mRCC), said Kathryn E. Beckermann, MD, PhD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication